Loading…
Loading…
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Picard between September 2, 2025, and October 31, 2025 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world's first and only total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the second quarter ended June 30, 2026.
/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 9, 2026 In the
/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 3, 2026 In the
–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– –First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform–
-First scientific presentation of the Emperor Drive System architecture to the biomedical engineering community- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first and only total artificial heart approved by the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that Taha Hasekioglu, Director, Office of the COO & Emperor Program Lead, will present new engineering insights into the Company's next-generation Emperor Total Artificial Heart (Emperor TAH) system during the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2026), taking place July 26–30, 2026, in Toronto, Canada.
-Company continues advancing long-term growth strategy under accepted compliance plan- -Company continues advancing long-term growth strategy under accepted compliance plan-